Aspirin, Birthweight, and Large‐For‐Gestational‐Age Neonates: A Secondary Analysis of the ASPRE Trial
BJOG: An International Journal of Obstetrics & Gynaecology · 2025-10 · 132 (11) · 1606-1614
DOI: 10.1111/1471-0528.18263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2025-07. Verfasst von Daniel L Rolnik und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Aspirin, Birth Weight, Fetal Macrosomia, Pre-Eclampsia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FP7 Health.
Abstract (Originalsprache)
Objective
To investigate the effects of aspirin on the distribution of birthweight and its impact on the rates of large‐for‐gestational‐age (LGA) neonates.
Design
Secondary analysis of the Combined Multimarker Screening and Randomised Patient Treatment with Aspirin for Evidence‐based Preeclampsia Prevention (ASPRE) trial.
Setting
Thirteen hospitals in England, Spain, Belgium, Greece, Italy and Israel. Population Participants of the ASPRE trial at increased risk of preterm pre‐eclampsia (PE) who had a live birth.
Methods
We compared the birthweight distributions and the rates of LGA neonates between the trial groups. Analyses were stratified according to the presence of pre‐existing diabetes mellitus and the development of PE, and logistic regression was used to investigate independent predictors of LGA neonates with birthweight above the 90th percentile. Main Outcome Measures Birthweight distribution and rates of LGA neonates.
Results
Among 1571 singleton, live neonates (777 from the aspirin group and 794 from the placebo group), aspirin was associated with a shift in birthweight from < 2500 to 2500–4000 g, and birthweight percentile from < 25th to 25th—75th percentiles, with no significant increase in LGA neonates (5.5% vs. 6.2%, p = 0.667). Logistic regression demonstrated a significant interaction between treatment and pre‐existing diabetes ( p ‐value 0.034), and a positive association between maternal weight and LGA neonates (adjusted odds ratio 1.040, 95% confidence interval 1.030–1.051, p < 0.001).
Conclusions
Aspirin use is associated with increased birthweight without increasing the rate of LGA neonates. Among women with pre‐existing diabetes, aspirin may be associated with a higher rate of LGA neonates, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia.
- Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
- Fetal Medicine Research Institute, King's College Hospital, London, UK.
- Institute of Health Research, University of Exeter, Exeter, UK.
- Coombe Women & Infants University Hospital, Dublin, Ireland.
- Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
ORCID-Profile: Daniel L Rolnik, Liona C Poon, Argyro Syngelaki, Neil O'Gorman, Catalina de Paco Matallana, Ranjit Akolekar, Francisca S Molina, Nicola Persico, Jacques C Jani, Walter Plasencia, Hamutal Meiri, Kypros H Nicolaides
Förderung
- FP7 Health
Zitieren
APA
Rolnik, D. L., Poon, L. C., Syngelaki, A., Wright, D., O'Gorman, N., de Paco Matallana, C., Akolekar, R., Janga, D., Singh, M., Molina, F. S., Persico, N., Jani, J. C., Plasencia, W., Papaioannou, G., Tenenbaum-Gavish, K., Meiri, H., & Nicolaides, K. H. (2025). Aspirin, Birthweight, and Large‐For‐Gestational‐Age Neonates: A Secondary Analysis of the ASPRE Trial. BJOG: An International Journal of Obstetrics & Gynaecology, 132(11), 1606-1614. https://doi.org/10.1111/1471-0528.18263
Vancouver
Rolnik DL, Poon LC, Syngelaki A, Wright D, O'Gorman N, de Paco Matallana C, et al. Aspirin, Birthweight, and Large‐For‐Gestational‐Age Neonates: A Secondary Analysis of the ASPRE Trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2025;132(11):1606-1614. doi:10.1111/1471-0528.18263
BibTeX
@article{Rolnik2025,
author = {Rolnik, Daniel L and Poon, Liona C and Syngelaki, Argyro and Wright, David and O'Gorman, Neil and de Paco Matallana, Catalina and Akolekar, Ranjit and Janga, Deepa and Singh, Mandeep and Molina, Francisca S and Persico, Nicola and Jani, Jacques C and Plasencia, Walter and Papaioannou, George and Tenenbaum-Gavish, Kinneret and Meiri, Hamutal and Nicolaides, Kypros H},
title = {Aspirin, Birthweight, and Large‐For‐Gestational‐Age Neonates: A Secondary Analysis of the ASPRE Trial},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2025},
volume = {132},
number = {11},
pages = {1606--1614},
doi = {10.1111/1471-0528.18263}
}
EUVIMED